VJHemOnc Podcast

iwAL 2022 Session III: Novel targets, combinations and treatment strategies in AML

The 4th International Workshop on Acute Leukemias (iwAL) 2022 took place in Nice, France, and brought together leading experts in the field as they discussed several topics. In this podcast series, you will hear the latest updates in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and gain an insight into the sessions that took place at this year’s meeting.

In this podcast, Richard Stone, MD, Dana-Farber Cancer Institute, Boston, MA, David Sallman, MD, H. Lee Moffitt Cancer Center, Tampa, FL, and Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, discuss novel targets and combinations in AML, treatment approaches for patients with TP53-mutated disease, and more. 

Recent updates in CML: treatment strategies, clinical trials, and novel agents

The 10th Annual Meeting of the Society of Hematologic Oncology (SOHO) was held in Houston, TX, from September 28-October 1, and brought together leading experts to discuss recent advances in hematological malignancies.

In this podcast, you will hear from experts Jorge Cortes, MD, Augusta University, Augusta, GA, and Mhairi Copland, MB ChB, PhD, University of Glasgow, Glasgow, UK, who discuss the latest in chronic myeloid leukemia (CML), including treatment strategies for patients with multiple refractory disease, and novel agents in the field. The experts also comment on clinical trial updates, including data from the OPTIC trial (NCT02467270) and the ASCEMBL trial (NCT03106779).

iwNHL Session II: Understanding and harnessing the immune microenvironment against lymphoma

The 19th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2022 took place in Barcelona, Spain, and brought together leading experts in the field as they discussed several topics. In this podcast series, you will hear the latest updates in NHL and gain an insight into the sessions that took place at this year’s meeting.

The second session from iwNHL focused on the role of the tumor immune microenvironment in lymphoma. In this podcast, John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci, Barts Cancer Institute, London, UK, Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, John Kuruvilla, MD, FRCPC, Princess Margaret Cancer Center, Toronto, Canada, and Gaël Roué, PhD, Josep Carreras Leukemia Research Institute, Barcelona, Spain, discuss the importance of understanding the tumor immune microenvironment in NHL. The experts outline strategies to engage the innate and adaptive anti-tumor immune response, and explain how this can be used to enhance the efficacy of immune therapies. 

iwAL 2022 Session II: Novel treatment strategies in ALL

The 4th International Workshop on Acute Leukemias (iwAL) 2022 took place in Nice, France, and brought together leading experts in the field as they discussed several topics. In this podcast series, you will hear the latest updates in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and gain an insight into the sessions that took place at this year’s meeting.

In this podcast, Robin Foà, MD, Sapienza University of Rome, Rome, Italy, Rob Pieters, MD, PhD, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands, Nicholas Short, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Nicolas Boissel, MD, PhD, Saint-Louis Hospital, Paris, France, discuss novel treatment strategies in ALL, including the role of combination approaches and antibody drug conjugates, and more.

The role of the innate immune system in MDS

Myelodysplastic syndromes (MDS) represent a heterogeneous group of diseases which remain a challenge to treat, and immune dysregulation has been found to play a key role in the pathogenesis of MDS. There is a growing interest, by researchers, as well as clinicians, to better understand the role of the innate immune system in this disease, and further investigate novel agents and strategies to treat patients at an earlier stage. 

In this podcast, you will hear from leading experts Rafael Bejar, MD, PhD, University of California San Diego, San Diego, CA, Rashmi Kanagal-Shamanna, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and David Sallman, MD, Moffitt Cancer Center, Tampa, FL, who discuss the role of the innate immune system in MDS, and further highlight the role of chronic inflammation in this disease, as well as future therapeutic strategies. 

iwAL 2022 Session I: The standard of care in AML in 2022

The 4th International Workshop on Acute Leukemias (iwAL) 2022 took
place in Nice, France, and brought together leading experts in the field as
they discussed several topics. In this podcast series, you will hear the
latest updates in acute myeloid leukemia (AML) and acute lymphoblastic
leukemia (ALL) and gain an insight into the sessions that took place at this
year’s meeting.

The first session from iwAL focused on the standard of care in AML in
2022. In this podcast, Mark Levis, MD, PhD, Johns Hopkins Sidney Kimmel
Comprehensive Cancer Center, Baltimore, MD, Eunice Wang, MD, Roswell
Park Comprehensive Cancer Center, Buffalo, NY, Jessica Altman, MD,
Robert H. Lurie Comprehensive Cancer Center, Northwestern University,
Chicago, IL, and Charles Craddock, CBE, FRCP, FRCPath, DPhil, University
of Birmingham, Birmingham, UK, discuss and debate the current standard
of care in AML in 2022, commenting on the role of transplantation and
novel agents, as well as treatment approaches for relapsed FLT3-mutated
disease.

iwNHL 2022 Session I: Advances in the treatment of T-cell lymphoma

The 19th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2022 took place in Barcelona, Spain, and brought together leading experts in the field as they discussed several topics. In this podcast series, you will hear the latest updates in NHL and gain an insight into the sessions that took place at this year's meeting.

The first session from iwNHL focused on advances in the treatment and management of T-cell lymphoma. In this podcast, Laurence de Leval, MD, PhD, Lausanne University Hospital, Lausanne, Switzerland, Steven Horwitz, MD, PhD, Memorial Sloan-Kettering Cancer Center, New York, NY, François Lemonnier, MD, Henri Mondor University Hospital, Créteil, France, and David Sibon, MD, PhD, Henri Mondor University Hospital, Créteil, France, discuss the safety and efficacy of brentuximab vedotin in enteropathy-associated T-cell lymphomas (EATL), epigenetic drugs and TRBC1-directed CAR-T therapy in T-cell lymphoma, and novel developments in the field of cutaneous T-cell lymphoma (CTCL). 

ISA 2022: meeting highlights and recent updates in amyloidosis

The 18th Meeting of the International Society of Amyloidosis (ISA) was held in Heidelberg, Germany, on 4-8 September, 2022. This meeting brought together experts in amyloidosis as they discussed the latest updates in the field, including novel therapeutic approaches, clinical trial updates, and recent advances in the diagnosis and management of this disease.

In this exclusive podcast, you will hear from experts Shaji Kumar, MD, Mayo Clinic, Rochester, MN, and Ashutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM, University College London, London, UK, as they share their highlights from this year's meeting. Topics covered in this podcast include the evolution of diagnostic approaches in light chain (AL) amyloidosis, advances in imaging techniques, and the role of hematopoietic stem cell transplantation (HSCT) in the era of daratumumab-based therapies. 

Highlights from IMS 2022: managing high-risk & frail patients with myeloma and the prognostic value of MRD

The 19th International Myeloma Society (IMS) Annual Meeting was held in Los Angeles, CA, and brought together experts in the field, who discussed several fascinating topics, including novel treatment strategies in multiple myeloma, the prognostic value of measurable residual disease (MRD), managing patients with high-risk disease, and more. 

In this exclusive podcast, Charlotte Pawlyn, BA, MBBChir, MRCP, PhD, FRCPath, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK, and Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, University College London Hospitals NHS Foundation Trust, London, UK, hold a fascinating discussion on the management of high-risk patients, highlighting data from several UK clinical trials. The experts also discuss the prognostic value of MRD and its application in clinical practice, the management of frail patients, and further comment on the recent approval of teclistamab by the European Medicines Agency (EMA). 

Highlights from the 2022 Texas MPN Workshop: early intervention, disease progression & future targets

The 2022 Texas MPN Workshop was held in San Antonio, TX, and covered several fascinating topics in the field of myeloproliferative neoplasms (MPNs). MPNs represent a heterogeneous group of diseases that remain a challenge to diagnose and treat. Several experts agree that early intervention and better understanding disease progression are crucial aspects to consider when treating patients, and studies investigating this are underway.

In this exclusive podcast, you will hear from experts Andrew Kuykendall, MD, H. Lee Moffitt Cancer Center, Tampa, FL, and Angela Fleischman, MD, PhD, University of California Irvine, Irvine, CA, as they share some insights into disease progression in MPNs, the importance of early intervention, and future targets.